Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
Start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from Oséo
August 27, 2009
- Approval by the French regulatory authorities of a first Phase IIa clinical trial with IPH 2101 in patients suffering from Multiple Myeloma, a severe haematological cancer
- Conducted in France, this multicenter trial will be supported by a 2.9 million euros grant from Oséo
- Other Phase IIa trials with IPH 2101 are being planned
| Download Area |
|---|
| PR in english |
| CP en français |